Insulins: Price Cut Aftermath and Pipeline Review

IPD’s new podcast release, "Insulins: Price Cut Aftermath and Pipeline Review," discusses the effects of the recent insulin price cuts by Eli Lilly, Novo Nordisk, and Sanofi, driven by the Inflation Reduction Act (IRA).

During the episode, Stephanie Tran, PharmD, BCPS, covers key topics, including the impact on PBM exclusion lists, changes in formulary management, the discontinuation of Novo's Levemir, and developments in the insulin pipeline, such as Novo's insulin icodec and Lilly's insulin efsitora alfa, both once-weekly basal insulins under FDA review.